Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | FABP6 | P51161 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 5/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PKMYT1 | Q99640 | 5/20 | 0.34 |
| ▸ | WEE1 | P30291 | 3/20 | 0.34 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL6314917 | 0.81 | PLAU (0.39) | PLAUFABP6ABL1QTRT1TYMS | |
| Carbamic Acid SCHEMBL6323888 | 0.76 | TYMS (0.44) | FABP6ABL1QTRT1TYMSPDE3B | |
| SCHEMBL2541923 | 0.74 | FABP6 (0.46) | PLAUFABP6QTRT1TYMSPDE3B | |
| SCHEMBL27759850 | 0.71 | HTR3E (0.44) | PLAUFABP6TYMS | |
| SCHEMBL6579702 | 0.69 | ALDH1A1 (0.48) | TYMS | |
| SCHEMBL21708401 | 0.67 | ALDH1A1 (0.48) | PLAUQTRT1TYMS | |
| SCHEMBL4244593 | 0.66 | ALDH1A1 (0.46) | FABP6ABL1QTRT1 | |
| SCHEMBL28171197 | 0.65 | TYMS (0.38) | PLAUTYMSPDE3BPDE3A | |
| Carbamic Acid SCHEMBL11093102 | 0.65 | KMT2A (0.78) | PLAUFABP6ABL1QTRT1 | |
| SCHEMBL21789938 | 0.65 | PLAU (0.38) | PLAUFABP6ABL1QTRT1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-09-01 | — | — | US | disclosed |
| US-6900235-B1 | Benzimidazole compounds, and pharmaceutical compositions and unit dosages thereof | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-6864275-B1 | Anticancer agents; viricides | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-03-08 | — | — | US | disclosed |
| US-6710065-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER OR A VIRAL INFECTION | UAF TECHNOLOGIES AND RESEARCH, LLC | 2004-03-23 | — | — | US | disclosed |
| US-6482843-B1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | THE PROCTER & GAMBLE COMPANY | 2002-11-19 | — | — | US | disclosed |
| US-6423735-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6423736-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTOR & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6420411-B1 | BENZIMIDAZOLE DERIVATIVES USED TO TREAT MELANOMA, LEUKEMIA, AND COLON, BREAST, LUNG, PANCREATIC, OVARIAN, AND PROSTATE CANCER; USED TO TREAT HIV; IMPROVED WATER SOLUBILITY | THE PROCTER & GAMBLE COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-6407131-B1 | 5-CARBONYLOXY-1H-BENZIMIDAZOLE-2-CARBAMATE DERIVATIVES | THE PROCTER & GAMBLE COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | PAICS, PIGO, BAD | PLAU 1297/4885FABP6 1633/4885ABL1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.